{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-076627","form_type":"8-K","ticker":"ARMP","cik":"0000921114","company_name":"Armata Pharmaceuticals, Inc.","filed_at":"2026-06-23T11:10:57+00:00","discovered_at":"2026-06-23T11:15:00.297675+00:00","generated_at":"2026-06-23T11:15:10.928966+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Armata Pharma receives $2.5M additional DoD funding for AP-SA02 Phase 3 readiness","bullets":["Received $2.5M additional non-dilutive funding from U.S. DoD; total DoD award now $28.7M for AP-SA02 development.","Funding supports Phase 3 readiness of AP-SA02, a bacteriophage therapy for complicated Staphylococcus aureus bacteremia.","Company plans to initiate Phase 3 superiority study of AP-SA02 in H2 2026.","DoD funding provided via MTEC and managed by NMRC/NAMD; non-dilutive nature preserves shareholder value."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-076627","json":"https://secwatch.observer/filing/0001104659-26-076627.json","markdown":"https://secwatch.observer/filing/0001104659-26-076627.md","text":"https://secwatch.observer/filing/0001104659-26-076627.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921114/000110465926076627/0001104659-26-076627-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921114/000110465926076627/tm2618503d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T11:15:10.928966+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}